

2015

Oncology Section EDGE Task Force on Breast Cancer Outcomes: A Systematic Review of Outcome Measures for Functional Mobility

Mary Insana Fisher

University of Dayton, mary.fisher@udayton.edu

Jeannette Lee

University of California - San Francisco

Claire Davies

Baptist Health Lexington

Hannah Geyer


University of Dayton

Genevieve Colon

University of Michigan - Flint

See next page for additional authors

Follow this and additional works at: https://ecommons.udayton.edu/dpt_fac_pub

 Part of the [Biomechanics Commons](#), [Musculoskeletal System Commons](#), [Oncology Commons](#), [Orthopedics Commons](#), [Sports Sciences Commons](#), and the [Therapeutics Commons](#)

eCommons Citation

Fisher, Mary Insana; Lee, Jeannette; Davies, Claire; Geyer, Hannah; Colon, Genevieve; and Pfalzer, Lucinda, "Oncology Section EDGE Task Force on Breast Cancer Outcomes: A Systematic Review of Outcome Measures for Functional Mobility" (2015). *Physical Therapy Faculty Publications*. 49.

https://ecommons.udayton.edu/dpt_fac_pub/49

This Article is brought to you for free and open access by the Department of Physical Therapy at eCommons. It has been accepted for inclusion in Physical Therapy Faculty Publications by an authorized administrator of eCommons. For more information, please contact frice1@udayton.edu, mschlangen1@udayton.edu.

Author(s)

Mary Insana Fisher, Jeannette Lee, Claire Davies, Hannah Geyer, Genevieve Colon, and Lucinda Pfalzer

Oncology Section EDGE Task Force on Breast Cancer Outcomes: A Systematic Review of Outcome Measures for Functional Mobility

Mary Insana Fisher, PT, PhD, OCS, CLT¹; Jeannette Lee, PT, PhD²;
Claire C. Davies, PT, PhD, CLT-LANA³; Hannah Geyer, BS⁴; Genevieve Colon, PT, DPT⁵;
Lucinda Pfalzer, PT, PhD, FACS, FAPTA⁶

¹Assistant Professor, Department of Physical Therapy, University of Dayton, Dayton, OH

²Assistant Professor, University of California-San Francisco/San Francisco State University Graduate Program in Physical Therapy, San Francisco, CA

³Physical Therapist, Rehabilitation Services, Baptist Health Lexington, Lexington, KY

⁴Student Physical Therapist, University of Dayton, Dayton, OH

⁵University of Michigan – Flint, Flint, MI

⁶Professor Emerita, Physical Therapy Department, University of Michigan – Flint, Flint, MI

ABSTRACT

Background: Breast cancer treatments in women with breast cancer often result in physical impairments that lead to activity limitations and participation restrictions. These limitations and restrictions manifest in impaired functional mobility skills that may impact survivorship. Thus, evaluation of functional mobility is an important part of survivorship care. **Purpose:** To identify functional mobility outcome measures that possess strong psychometric properties and are clinically useful for examination of women treated for breast cancer. **Methods:** Multiple electronic databases were searched for articles published after 1995. Studies were included if they reported psychometric properties, used clinically feasible methods, were performed on adults, and published in the English language. Each outcome measure was independently evaluated and rated by two reviewers. A single Cancer EDGE Task Force Outcome Measure Rating Form was completed for each category of functional mobility, and a recommendation was made using the 4-point Cancer EDGE Task Force Rating Scale. **Results:** Of the original 819 articles found, 211 were included in this review. A total of 11 measures are recommended for clinical use: the Timed Up and Go; the 2-Minute, 6-Minute, and 12-Minute Walk Tests; 10-Meter Walk; 5 Times Sit to Stand; Short Performance Physical Battery; Physical Battery for Patients with Cancer; Functional Independence Measure (FIM); Assessment of Life Habits; and Activity Measure for Post-acute Care. **Conclusions:** Many tools are available to assess upper extremity and overall functional mobility skills in women

treated for breast cancer. There are currently no tools recommended that assess community participation.

Key Words: breast neoplasms, outcome assessment, patient-reported outcomes, psychometrics

INTRODUCTION

Breast cancer is the most common form of cancer in women in the United States with approximately 12% developing breast cancer in their lifetime.¹ In 2015, an estimated 231,840 new cases of invasive breast cancer in women will be diagnosed, and in 2011 an estimated 2,889,726 women were living with breast cancer.¹ There are approximately 3 million women diagnosed with breast cancer surviving today.¹ For all stages of breast cancer combined, the 5-, 10-, and 15-year relative survival rates are 89%, 83%, and 78%, respectively.¹ As the number of breast cancer survivors (BCS) continues to grow, many women will develop significant impairments of multiple body systems and functions.²

Functional mobility is an essential physical ability categorized within the activities and participation domains of the International Classification of Functioning, Disability, and Health (ICF).³ Abilities related to changing and maintaining body position including carrying, moving, and handling objects, and walking and moving, fall under the Mobility domain.³ The Self-Care domain contains abilities related to washing oneself, toileting, dressing, eating, and drinking, while the Domestic Life domain includes acquisition of necessities, household tasks, and caring for and assisting others.³ The categories of functional measures evaluated in this review fall under these specific subdomains of the ICF. Whether a BCS can safely move about, complete self-care activities, and partake in domestic life must be assessed as part of the rehabilitation evaluation. Other measures used to detect and quantify impairments in functional mobility include additional upper extremity functional tests, tests for activities of

Address correspondence to: Mary I. Fisher, PT, PhD, OCS, CLT, Department of Physical Therapy, University of Dayton, 300 College Park, Dayton, OH 45469 Ph: (937) 229-5617, Fax: (937) 229-5601 (mary.fisher@udayton.edu).

daily living, walk tests, and self-report questionnaires identifying impairments with community participation. Determining which measures of functional abilities are reliable and valid in this population provides a means for accurate and thorough assessment of function.

Treatment for breast cancer is generally comprised of surgery and adjuvant strategies. Surgical interventions include removal of the tumor and surrounding tissue or mastectomy, which is the surgical removal of the breast. Treatments may also involve radiation therapy, chemotherapy that can be administered before or after surgery, targeted therapy, and/or hormone therapy such as selective estrogen receptor modifiers, aromatase inhibitors, and ovarian ablation.¹ The impact of cancer treatments on overall function has been explored in the literature, and findings suggest that the cancer experience has a long-term negative influence on activity and participation abilities of survivors. Complications from cancer and its treatments may affect some patients' functional mobility such as their ability to lift and carry objects, handle objects, complete self-care activities, and even walk and move about to carry out these daily activities.⁴⁻⁸ Nearly 25% of cancer survivors report difficulty walking,⁹ reported more functional limitations than women without cancer,¹⁰ and generally scored lower on the Short Form-36 (SF-36), a patient-reported measure that assesses health-related quality of life.¹¹ In a study of cancer survivors post-treatment, the majority of whom were BCS, 22% had difficulty walking and 30% had participation restrictions.¹² The Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH), a 30-item patient outcomes assessment designed to evaluate disorders of the upper limbs and monitor change or function over time, has been used to capture upper extremity dysfunction in women with or post breast cancer.¹³ In survivors 6 months after diagnosis and treatment, 25.6% had a score greater than 20, where a higher score denotes greater disability. Scores greater than 20 indicate an impairment of motor function.¹³ At a 6-year follow-up, 21.1% had continued dysfunction with scores above 20.¹⁴ Certainly, researchers have established that women with limitations in upper extremity range of motion and strength also report greater difficulties with activities of daily living (ADLs) and lower overall arm function on self-reported questionnaires.¹⁴⁻¹⁶ Declines in activities and participation seen in this population often translate to changes in overall quality of life.

In 1991, the Task Force on Standards for Measurement in Physical Therapy (a committee of the American Physical Therapy Association [APTA]) established the criteria for valid, reliable, objective, and standardized tests and measures to assist clinicians in providing the highest quality of care.¹⁷ The criteria for appropriate outcome measures needs to consider the following elements: (1) measurement of a domain within the ICF; (2) purpose of the measure relevant to obtaining discriminative, predictive, or evaluative information; (3) disease specific vs. general measure; self-report vs. performance-based measure; (4) patient's ability and goals; (5) psychometric properties, particularly reliability, validity, diagnostic accuracy, minimal detectable change (MDC),

and minimal clinical important difference (MCID); and (6) feasibility, including the time, equipment, cost, space, and training required to administer and score the test results, overall burden on the patient to complete the test, and consideration of cultural and language barriers.¹⁸ The use of standardized outcome measures is an essential component of evidence-based practice and enhances the communication with patients and payers.¹⁹ The main barriers to a standardization of physical therapy outcome measures include both the length of time and difficulty for patients to complete the test, as well as the time necessary for clinicians to administer the test and interpret the results.¹⁹

In 2010, the Oncology Section of the APTA created the Evaluation Database to Guide Effectiveness (EDGE) Task Force to critically review and recommend outcome measures to be used when assessing the status of cancer survivors.²⁰ The Breast Cancer EDGE Task Force subcommittees have provided recommendations for outcome measures in the areas of shoulder and upper quarter function,^{21,22} scapular assessment,²³ strength and muscular endurance,²⁴ pain,²⁵ fatigue,²⁶ balance and peripheral neuropathy,²⁷ health-related quality of life,²⁸ and cardiovascular fitness.²⁹

This systematic review continues the ongoing efforts of the EDGE Task Force and evaluates the ways in which functional mobility is measured clinically in individuals with breast cancer. These tools provide important information about the patient, focus intervention strategies, and measure treatment effectiveness, addressing the survivorship needs of women treated for breast cancer. The reliability, validity, MDC, and/or MCID are important psychometric properties that need to be established and assessed to justify the use of the selected outcome measures in the clinic.¹⁸ In addition, tools used to track and measure patient outcomes should be validated in the population in which they are used to be most beneficial for the patient. Lastly, these tools need to be considered in light of clinical utility, including the availability of resources, cost, ease of use, and availability of normative data. The purpose of this systematic review is to make recommendations of the best methods to evaluate functional mobility in BCS based on psychometric properties and clinical utility.

METHODS

Search Strategy

The authors systematically investigated the literature for outcome measures that directly measured functional mobility to evaluate the psychometric properties and clinical utility for use assessing BCS. The primary literature search took place during February and March of 2014 using 8 electronic databases: Google Scholar, Ovid, PubMed/Medline, CINAHL, Sports Discus, Web of Science, Cochrane Review, and PEDro. Search terms that were used included breast cancer or neoplasm in addition to multiple terms describing functional mobility including function, mobility, and limb use. The name of established functional tests were also specifically searched (refer to Appendix 1 for full list of search terms). Note that this list exceeds the number of functional tests investigated in this review. The final list includes only those

measures that were deemed to assess functional mobility skills, and that had published reports available for analysis. It is possible that outcome measures were omitted if the search did not reveal published information on the test.

Study Selection

To be included in this review, studies (1) were published in English; (2) performed tests of functional mobility; (3) reported psychometric properties; (4) presented clinically feasible methods; and (5) included adults (≥ 18 years), preferably women. Included articles were considered if published from 1/1/1995-present. The breast cancer population took first priority within the search, however, if no studies included this population, women with other cancers, geriatric patients, and the general population were considered for review.

Data Extraction

Teams of two reviewers independently performed data extraction using the Cancer EDGE Task Force Rating Form.²⁰ Tests of functional mobility were categorized into one of 4 groupings: (1) upper extremity functional tests, (2) ADL functional tests, (3) walk tests, and (4) self-report community participation tests. The categories for functional mobility were selected based on the qualities and foci of the functional outcome measures. Each functional category included a series of tests and assessments. Refer to Appendix 2 for tests listed under each category. Following data extraction, reviewers independently appraised each outcome measure using all articles covering the outcome measure of interest. Outcome measures were rated 1-4 using the Cancer EDGE Task Force Rating Scale (Figure 1), taking into consideration both psychometric properties and clinical utility. Outcome measures rated differently by each reviewer were discussed with 4 primary reviewers until consensus was obtained.

RESULTS

The initial literature search for functional mobility testing in survivors of breast cancer resulted in 819 articles. The assessors reviewed all the titles and any duplicates were removed. A total of 297 articles were retrieved and assessed for eligibility. Abstract and article titles were then examined to identify studies that addressed the specific purpose of the research. After exclusions were applied, 211 articles were reviewed. See Figure 2 for flow diagram of literature search.

The number of articles reviewed for each category of tests were: (1) upper extremity functional tests—37, (2) ADL functional tests—23, (3) walk tests—101, and (4) self-report community participation tests—53. Some research studies evaluated multiple tools; therefore, the number of articles for each category is not mutually exclusive. Table 1 delineates the clinical usefulness of the recommended tests.

Eleven measures are recommended by the Breast Cancer EDGE Task Force members for use to measure the functional mobility skills of BCS in the clinic. These 11 measures are rated 3 or 4 on the Task Force rating scale. Two measures are highly recommended (4) having been used in research with breast cancer: the 6-Minute Walk Test (6MWT) and the Timed Up and Go (TUG). Nine are recommended (3): 2-Minute and 12-Minute Walk, 10-Meter Walk, 5 Times Sit to Stand, Short Performance Physical Battery, Physical Battery for Patients with Cancer, Functional Independence Measure (FIM), Assessment of Life Habits, and Activity Measure for Post-acute Care. The Task Force is unable to recommend 10 measures due to lack of psychometric support or poor clinical utility. Two measures scored a 2A: Barthel Index and Reintegration in to Normal Living; 8 scored a 2B: Canadian Occupational Performance Measure, Impact on Participation and Autonomy Questionnaire, Life Satisfaction Questionnaire, Modified Rankin Scale, Timed 25 Foot Walk, Arm Mobility Ability Test, Wolf Motor Function Test, Action Research Arm Test. Finally, 4 measures are not recommended (1): Functional Status Examination, Participation Objective Participation Subjective, Participation Survey of Mobility Limited People, and 6-Minute Arm Test. See Tables 2 (recommended outcome measures) and 3 (not recommended outcome measures) with Task Force ratings and clinical utility comments. Detailed psychometric properties of the recommended clinical measures of functional mobility testing in BCS can be found in Table 4 (supplemental online table provides detail for all reviewed outcome measures).

Discussion

The purpose of this review was to systematically identify and review methods of evaluating functional mobility in BCS and to make recommendations about these outcome measures based on psychometric properties and clinical utility. Since functional mobility comprises activities that enable an individual

4	Highly Recommend	Highly recommended; the outcome has good psychometric properties and good clinical utility. The measure has been used in research on individuals with or post breast cancer.
3	Recommend	Recommended; the outcome measure has good psychometric properties and good clinical utility. No published evidence that the measure has been applied to research on individuals with or post breast cancer.
2A	Unable to Recommend at this time	Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure. The measure has been used in research on individuals with or post breast cancer.
2B	Unable to Recommend at this time	Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure. No published evidence that the measure has been applied to research on individuals with or post breast cancer.
1	Do Not Recommend	Do not recommend; poor psychometrics &/or poor clinical utility (time, equipment, cost, etc.)

Figure 1. Breast Cancer EDGE Task Force rating scale.




Figure 2. Flow of literature search.

to move about in their environment in order to perform ADLs and participate in life situations,³⁰ the measures reviewed by the Breast Cancer EDGE Task Force members span upper extremity functional tests, ADL tests, walk tests, and self-report community participation questionnaires. Eleven measures are rated 3 (recommend) or 4 (highly recommend).

The ability to complete functional mobility tasks is a necessary part of the rehabilitation experience. Although the upper limb is the most obvious body part on which to focus, overall

functional mobility of BCS should be included in assessment. It is for this reason that all levels of functional mobility were evaluated in this review.

Upper Extremity Functional Tests

Of the upper extremity functional tests included in this review, only one, the Activity Measure for Post-Acute Care (AM-PAC), was recommended (rated 3). The AM-PAC assesses activity limitations based on the ICF model for patients across the post-acute care setting with varying diagnoses.³¹ The AM-PAC measures activity limitations in 3 distinct domains: basic mobility, daily activities, and applied cognitive; and it is available in two formats: a computer-based version and a short form version.³² The number of items varies depending on the format, as well as the setting (eg, in-patient vs. out-patient). The measure is very thorough and comprehensive, and has undergone substantial psychometric testing and validation, but because the instrument is meant to apply across many settings to as wide a patient population as possible, the specificity and sensitivity might be decreased. The AM-PAC was used in studies with other cancer diagnoses, but not specifically for BCS. There is a fee associated with use of the instrument and scoring is not intuitive.

Activities of Daily Living Functional Tests

Two measures, the FIM and the Assessment of Life Habits (LIFE-H), were rated 3 (recommended). The FIM is a widely used uniform measurement system for evaluating basic quality of daily living activities in persons with a disability.³³ The FIM is comprised of 18 items (13 motor tasks and 5 cognitive tasks) and assesses the amount of assistance an individual requires to complete the activities safely and effectively. Items include skills

Table 1. Clinical Usefulness of Recommended Measures

Measure	Equipment Needed	Cost	Ease of Use	Scoring/ Interpretation	Normative Data
6-Minute Walk	Yes – Stopwatch	Free	High	Easy	Yes
Timed Up & Go	Yes – Stopwatch, chair, measuring tape	Free	High	Easy	Yes
5 Times Sit to Stand	Yes – Stopwatch, standard chair	Free	High	Easy	Yes*
2-Minute Walk	Yes – Stopwatch	Free	High	Easy	Yes*
12-Minute Walk	Yes – Stopwatch	Free	High – patient may be limited by condition	Easy	Yes*
10-Meter Walk	Yes - Stopwatch	Free	Medium – varied procedures	Easy	Yes*
Short Performance Physical Batter	Yes – Stopwatch, chair, measuring tape, cones	Free	High	Easy	Yes*
Physical Battery for Patients with Cancer	No	Free	High - poor reliability for balance	Difficult	Yes*
Functional Independence Measure	Yes – varies based on category	Moderate	Low – training required	Moderate	Yes
Assessment of Life Habits	No	Minimal	High	Difficult	Yes*
Activity Measure for Post-acute Care	No	Minimal	Medium	Moderate	Yes*

*Not validated in breast cancer populations

Table 2. Recommended Outcome Measures

Measure	Breast Cancer EDGE Task Force Rating	Clinical Utility
6-Minute Walk	4	Good clinical utility, free and easy to administer. Evidence with BCS.
Timed Up and Go	4	Good clinical utility, free and easy to administer. Evidence with BCS.
5 times sit to stand	3	Good clinical utility, free and easy to administer, not used in BCS.
2-Minute Walk	3	Good clinical utility, free and easy to administer, not used in BCS.
12-Minute Walk	3	Free to administer but limited clinically with lower functioning individuals.
10-Meter Walk	3	Free and easy to administer, not used in BCS.
Short Performance Physical Battery	3	Free to administer. Not established in BCS.
Physical Battery for Patients with Cancer	3	Specific to the cancer population. May not have time to use in the clinic.
Functional Independence Measure	3	Cost to purchase. 30-40 minutes to complete. Not valid in cancer population.
Assessment of Life Habits	3	Takes time to complete with challenging scoring. Lower clinical utility.
Activity Measure for Post-Acute Care	3	CAT version available. Based on WHO ICF. Not used in BCS.

Abbreviations: BCS, breast cancer survivors; WHO, World Health Organization; ICF, International Classification of Functioning; CAT, computer assisted testing

Table 3. Outcomes Measures Not Recommended

Measure	Breast Cancer EDGE Task Force Rating	Clinical Utility
Barthel Index	2A	Not used in the cancer population.
Reintegration into Normal Living/Life Index	2A	10 minutes to complete, insufficient information to recommend at this time.
Canadian Occupational Performance Measure	2B	Free to use. No evidence in use in BCS.
Impact on Participation and Autonomy Questionnaire	2B	30 minutes to complete, not used in cancer population.
Life Satisfaction Questionnaire	2B	10-30 minutes to complete, free, not used in cancer populations.
Modified Rankin Scale	2B	6-30 minutes to complete. Free to complete. Experience raters needed to decrease bias.
Timed 25 Foot Walk	2B	Easy to administer. Not validated in cancer population.
Arm Mobility Ability Test	2B	Lengthy time to complete and scoring is difficult. No evidence in BCS.
Wolf Motor Function Test	2B	Used in the neurological population but not used in BCS.
Action Research Arm Test	2B	Uses multiple pieces of equipment. Used in the neurological population but not used in BCS.
Functional Status Exam	1	6-30 minutes to complete. Used in the neurological population.
Participation Objective, Participation Subjective	1	6-30 minutes to complete. Not recommended, no evidence in cancer populations.
Participation Survey of Mobility Limited People	1	20-40 minutes to complete online or 60-90 minutes hard copy – lack of clinical feasibility.
6-Minute Arm Test	1	Used to assess cardiovascular fitness. No psychometric data and difficulty obtaining the equipment.
Hi-Level Mobility Assessment Tool	1	Developed specifically for high level traumatic brain injury.

Abbreviation: BCS, breast cancer survivor

related to self-care, sphincter control, transfers, locomotion, communication, and social cognition. The FIM was validated on a number of populations across a variety of settings with good psychometric properties.³⁴⁻³⁶ The FIM is a measure that physical

therapists are familiar with, and the tool has been used in studies with a BCS cohort. However, there is a cost associated with use of the FIM, training/certification is required prior to using the FIM, and it ideally is scored by consensus with a multi-disci-

Table 4. Psychometric Properties of Recommended Outcome Measures

Measure	Intra-rater Reliability	Inter-rater Reliability	Test/Re-test Reliability	Responsiveness to Change	Validity
Upper Extremity Functional Tests					
Activity Measure for Post-acute Care (not tested in cancer population)		Daily Activity: ICC = 0.90 ⁶³ Mobility: ICC = 0.86 ⁶³ Applied cognition: ICC = 0.68 ⁶³	Daily Activity: ICC = 0.96 ⁶³ Mobility: ICC = 0.97 ⁶³ Applied cognition: ICC = 0.91 ⁶³	MDC AMPAC Computer version ⁶⁴ basic mobility =4.28 points Daily activity = 3.7 points Applied cognitive = 5.55 MDC AMPAC CAT = 2 points ⁶⁵	With SF-36: r = .84 ⁶⁶ With Gait speed: r = 65 ⁶⁶ With 6MWT: r = 0.67 ⁶⁶ <u>Internal consistency</u> Cronbach alpha Total: 0.92-0.94 ⁶⁷ Specific dx groups: 0.90-0.95 ⁶⁷
Activities of Daily Living Functional Tests					
Functional Independence Measure (FIM) (not tested in cancer population)		ICC = 0.95 ⁶⁸	ICC = 0.80 - 0.90 ^{69,70}		With Barthel Index r = 0.92-0.94 ⁷¹
Assessment of Life Habits (LIFE-H) (not tested in cancer population)		ICC = 0.89 ⁷²	ICC = 0.74 - 0.89 ^{73,74}		With Craig Handicap Assessment and Reporting Technique: r = 0.14 - 0.76 ⁷⁵ With Community Integration Questionnaire: r = 0.54 - 0.75 ⁷⁵ <u>Internal Consistency:</u> Cronbach alpha = 0.82 - 0.90 ⁷⁵
Walk Tests					
2-minute walk test (not tested in cancer populations)	ICC = 0.83 – 0.98 ⁷⁶⁻⁸⁰ Coefficient of variation: r = .049 ⁸¹	ICC = 0.85 - 0.97 ^{78,79,82}	ICC = 0.94 - 0.95 ⁸²	SEM estimated ≤ 6.3m ⁸³ MDC (older adults): 13.4 - 14 m ^{79,82}	With TUG: r = -0.68 - 0.87 ^{82,83} With BBS: r = 0.88 ⁸² With 6MWT: r = 0.93 – 0.96 ^{82,84} With EDSS: r = -0.61 ⁸⁴ With MSWS-12: r = -0.72 ⁸⁴ With MFIS physical sub-index: r = 0.31 ⁸⁴
6-minute walk test	Other populations ICC = 0.74 - 0.99 ^{41,85}	Other populations: ICC = 0.78 - 0.99 ^{41,85}	Cancer population: ICC: 0.93 (0.86-0.97) ⁴⁰ Other populations: ICC = 0.94-0.99 ^{44,86-92} R = 0.95 ³	Cancer population: Coefficient of repeatability: 60m ⁴⁰ Small meaningful change: 20m ⁹³ Substantial meaningful change: 50m ⁹³	Cancer population: With: ⁴⁰ exercise capacity r = 0.67 maximum workload r = 0.70, perceived physical function r = 0.55 age r = -0.52 Other populations: With 10MWT: r = -.95 ^{92,94} With TUG: r = -0.88 ^{90,94,95} With Walking Index for SCI: r = 0.60 ⁹⁴ With 2MWT: r = 0.997 ⁸⁵ 12MWT: r = 0.994 ⁸⁵ 10m fast gait: r = 0.94 ⁹⁰ 10m comfortable gait: r = 0.84 ⁹⁰
12-minute walk test (not tested in cancer populations)	ICC = 0.71 ⁸⁷	ICC = 0.68 ⁸⁷		Standardized response mean (SRM) score = 1.90 ⁸⁷	
10-meter walk (not tested in cancer populations)	ICC = 0.98 ^{41,95}	ICC = 0.97 - 0.99 ^{41,95,96}	R = 0.75-0.90 ⁹⁷ ICC = 0.82 - 0.93 ^{56,66,90,98-100}	MDC .013 - 0.25m/s ^{89,95,101,102}	With dependence in self-care: r = 0.60 - .087 ¹⁰² With dependence in mobility: r = 0.34- .074 ¹⁰² With dependence in domestic life: r = 0.34 - 0.74 ¹⁰² With instrumental activities of daily living: r = 0.76 ¹⁰³ With Barthel Index: r = 0.78 ¹⁰³ With TUG: ICC = -0.84 to -0.91 ⁹⁰ With 6MWT: ICC = 0.89 – 0.95 ⁹⁰

Table 4 Continued.

Measure	Intra-rater Reliability	Inter-rater Reliability	Test/Re-test Reliability	Responsiveness to Change	Validity
Walk Tests – continued					
Timed Up & Go (Cognitive & Manual)			$r = 0.90^{104}$	MCID = 1 sec ¹⁰⁵	Cancer population: With falls within 1 year: $r = 0.85^{106}$ With falls within 3 months: $r = 0.85^{106}$ With falls since cancer diagnosis: $r = 0.74^{106}$ With Simmonds Performance Status Battery: $r = 0.85^{106}$ Other populations: With 5 times sit to stand: $r = 0.60^{104}$ With standing balance: $r = -0.31^{104}$ With Rapid Disability Rating Scale: $r = 0.42^{104}$ With S-36 physical function: $r = -0.50^{104}$ With 2MWT: $r = 0.68 - 0.81^{107}$
5 Times Sit to Stand (not tested in cancer populations)		ICC=0.99 ⁹⁹⁻¹⁰¹	$r = 0.82 - 0.99^{99-105}$	MDC 2.5 – 4.2sec ^{101,102,106} MCID ≥ 2.3 sec ¹⁰⁷	With PASE: $r = -0.38^{99}$ With PDQ-mobility: $r = 0.58^{99}$ With ABC: $r = 0.54 - 0.68^{99,107}$ With Mini-BEST: $r = 0.71^{99}$ With quads MVIC: $r = -0.33 - 0.65^{99,108}$ With 6MWT: $r = 0.60 - 0.75^{99,108}$ With 5MWT: $r = -0.78^{100}$ 50 foot walk: $r = 0.87^{100}$ Repeated trunk flexion: $r = 0.64^{100}$ With DGI: $r = -0.58^{107}$
Short Performance Physical Battery (SPPB) (not tested in cancer populations)	ICC >0.90 ¹¹⁸	ICC >0.90 ¹¹⁸	ICC = 0.82 – 0.92 ¹¹⁸⁻¹²¹	MDC 1.42 – 2.9 points (elderly) ^{66,93} 3.42 points (s/p hip fracture) ¹²²	With self-reported mobility = 89% ⁵⁹ With ADL associated disability = 96% ⁵⁹
Physical Performance Battery for Patients with Cancer		$r = 0.98$ and 0.99^{106}	$r = 0.69-0.99^{106}$		Cancer pop: Portions correlated with TUG: ¹⁰⁶ Walk test: $r = 0.85$ Sit to stand: $r = 0.74$ Sock test: $r = 0.55$ 6MWT: $r = -0.62$ Portions correlated with functional status: ⁸⁸ ADLs: $r = 0.39 - 0.43$ Forward reach: $r = 0.25$ Sit to stand: $r = 0.44$ 6MWT: $r = -0.49$

Abbreviations: ICC, intraclass correlation coefficient; r, Pearson's Coefficient Correlation; SEM, standard error of measurement; MDC, minimal detectable change; MCID, minimal clinical important difference; BCS, breast cancer survivors; QOL, quality of life; 2MWT, 2-minute walk test; 6MWT, 6-minute walk test; BBS, Berg Balance Scale; EDSS, Expanded Disability Status Scale; MSWS, Multiple Sclerosis Walking Scale; TUG, Timed Up and Go; MFIS, Modified Fatigue Impact Scale; AM-PAC, Activity Measure for Post-acute Care; CAT, Computer Adaptive Testing; SF-36, Short Form-36

plinary team. The test may take up to 45 minutes to administer/complete, which can affect its clinical utility.

The LIFE-H assesses the quality of an individual's social participation based on one's perception of difficulty experienced and how much assistance is required to complete a task.³⁷ The long and short form of the instrument (ver. 3.0) has 240 and 69 items, respectively, covering 12 domains including nutrition, personal care, mobility, interpersonal relationships, community life, and recreation. The LIFE-H is comprehensive and has good psychometric properties, however, Magasi and colleagues³⁸ point out that the LIFE-H was not widely used outside of the group

that developed the instrument, and the conceptual foundation on which the instrument was grounded was not widely known, limiting its adoption by the clinicians and researchers. The LIFE-H was not validated in the cancer population. Moreover, scoring of the instrument is difficult, and it may take an hour or more to complete the instrument (up to 60 minutes for the short form, up to 120 minutes for the long form).

Walk Tests

Walk tests fall under the ICF Mobility Domain. The ability to safely and efficiently walk and move about is considered an

essential life skill. The following tests were rated a 3 (recommended) or 4 (highly recommended) by the EDGE Task Force.

The 6MWT and the TUG were rated 4 (highly recommended). Both of these tests exhibit good psychometric properties, and were tested and used extensively with BCS. In the 6MWT, the individual is asked to walk as far as possible for a total of 6 minutes on a hard, flat surface; the patient is allowed to self-pace or rest as needed during the test.³⁹ This test was originally developed as a measure of exercise tolerance in patients with chronic respiratory disease and heart failure, but has since been used as a performance-based measure of functional capacity in many other populations.⁴⁰⁻⁴⁴ Among patients with cancer, the 6MWT exhibited good reliability, and the distance walked correlates well to exercise capacity and workload.⁴⁰ The 6MWT has been used to assess physical impairments following breast cancer treatment,⁴⁵ as well as functional improvements after exercise programs for BCS.⁴⁶⁻⁴⁸

The second highly recommended test, the TUG, measures the time in seconds for a person to rise from sitting in a standard chair with arms, walk 3 meters, turn, walk back to the chair, and sit down.⁴⁹ Thus, this test provides an overall assessment of elements that are important for independent mobility including sit to stand transfers, ambulation, and turning about in space. The TUG has good inter/intrarater reliability and is highly correlated with gait speed,⁵⁰ which in turn, is a significant predictor of functional dependency and disability.^{51,52} Among patients with cancer, the TUG was used as a measure of performance status, mobility, and postural control.^{51,53} Both the 6MWT and the TUG are free and easy to administer, requiring little to no equipment. The instructions for both tests are also available in many languages.

Six measures in the Walk Test category are rated recommended (rated 3). These tests include the 2-minute and 12-minute walk, 10-meter walk, as well as physical performance batteries that incorporated walk tests: Short Performance Physical Battery (SPPB), and the Physical Performance Battery for Patients with Cancer. The 5 times sit-to-stand test (FTSST or 5xSST) was also included in this category. The 2- and 12-minute walk tests (2MWT, 12MWT) are both variants of the 6MWT. The individuals walk as far as they can in 2 or 12 minutes, respectively. Like the 6MWT, individuals can rest or stop as needed, and use their customary walking aid. The 2MWT was proposed as an alternative to the 6MWT as being more clinically feasible for a patient with significant muscle weakness, gait inefficiency, or fatigue.⁵⁴ On the other hand, the 12MWT was proposed in response to the observation that patients tend to walk at a faster pace initially before settling to a more constant speed, thus a longer walk test would be a more accurate measure of functional capacity and exercise tolerance.⁵⁵ While both of these measures were tested in other populations and exhibit good clinical utility, the 2MWT has not been used, to our knowledge, on BCS. The 12MWT may have limited utility with BCS as the patients who have significant sequelae from breast cancer treatment (eg, peripheral neuropathy, cancer-related fatigue, etc) might have difficulty completing the test due to the longer time frame. The 10-meter walk (10MWT)

assesses the time it takes an individual to walk 10 meters. The distance is then divided by the time to complete that distance in order to derive gait speed. There are variations of this measure in which the individual walks at his/her preferred or fastest speed possible.⁵⁶ While this test is easy to administer, there are different reported methods for how to conduct the 10MWT, such as the use of extra distances to allow the individual to accelerate or decelerate.⁵⁷ Moreover, there is limited information on its use with BCS.

The SPPB and Physical Performance Battery for Patients with Cancer are both physical performance batteries. Each of these batteries attempts to capture a hierarchy of function for a variety of physical tasks that mimic daily activities. The SPPB captures mainly lower extremity function, while the Physical Performance Battery for Patients with Cancer also includes upper extremity tasks. The SPPB is composed of a balance task, a short walk at the usual speed, and 5 repetitive chair stands.⁵⁸ This test was designed such that it could be performed in almost all clinical and research settings, and to quantify physical performance changes over time.⁵⁹ The SPPB captures domains of strength, endurance, and balance, is relatively easy to administer, and was used extensively in studies in the older population. However, its use with BCS is limited, perhaps because lower extremity function is not perceived as an area of immediate concern compared to upper extremity function. Of note, Curb and colleagues⁶⁰ report that the balance subscale of the SPPB has poor reliability, and suggests using the summary SPPB score or a difference balance assessment tool if balance is the construct of interest.

The Physical Performance Battery for Patients with Cancer was devised specifically for the oncology population.⁶¹ This test battery has 9 separate individual tests. While the individual tests are relatively easy to administer/perform, the total time to complete the test battery may be up to 40 minutes. The Physical Performance Battery for Patients with Cancer was used in studies including BCS, however, the time it takes to complete the test battery as well as putting the results into context (ie, results of the battery vs. individual tests) may diminish its clinical usefulness.

The 5xSST assesses lower extremity strength and ability to perform transitional movements. Individuals are asked to stand up from a standard chair and sit down 5 times, as quickly as possible, while keeping arms folded across the chest.⁶² The 5xSST is quick and easy to administer and is a test within the SPPB. The 2 Times Sit to Stand is a test within the Physical Performance Battery for Patients with Cancer. There are other versions that were reported, such as a 30-second sit to stand, a 10 times sit to stand, and a single leg sit to stand. However, the 5xSST and other versions were not specifically tested in the cancer population.

Self-report Questionnaires/Community Participation

None of the reviewed scales for self-report and community participation are recommended by this Task Force. They either lacked psychometric testing or clinical utility presenting issues for the clinician as the dearth of quality scales leaves a void in accurate assessment. One might argue that some assessment is better than no assessment; however, should the assessment

be unreliable or lack validity, then it may not assess the given construct accurately. Because the Task Force cannot recommend any of the measures for self-report and community participation, using traditional descriptive techniques to define performance is recommended.

CONCLUSION

Assessing functional mobility is an important part of breast cancer survivorship. Many tools exist that accurately and reliably assess upper extremity functional mobility, activities of daily

living, walking, and community participation. Eleven measures are recommended for use by the Oncology EDGE Task Force. Tools that assess community functional mobility currently lack either psychometric validation or clinical utility, or both. Further research exploring community functional mobility for this population is necessary either to develop further existing tools or design new tools that possess both sound psychometric properties and good clinical utility. Survivorship care for women treated for breast cancer is enhanced by using the recommended measures.

Appendix 1. Search Terms

Primary search terms: breast cancer, neoplasm, function, functional mobility, limb use		
Secondary search terms:		
<ul style="list-style-type: none"> • 5 Times Sit to Stand • 10 Meter Walk Test • 2 Minute Walk Test • 6 Minute Walk Test • 12 Minute Walk Test • Action Research Arm Test • Activity Measure for Post-acute Care • Arm Motor Ability Test • Assessment of Life Habits • Barthel Index • Canadian Occupational Performance Measure • Clinical Test of Sensory Interaction and Balance • Community Balance and Mobility Scale 	<ul style="list-style-type: none"> • Functional Independence Measure • Functional Reach Test/Modified Functional Reach Test • Functional Self-assessment • Functional Status Examination • Goal Attainment Scale, • Hauser Ambulation Index • High-level Mobility Assessment Tool (HiMAT) • Impact of Participation and Autonomy Questionnaire (IPAQ) • Jebsen Taylor Arm Function Test • Life Satisfaction Questionnaire (LISAT-9) • Modified Rankin Scale 	<ul style="list-style-type: none"> • Motor Activity Log • Motricity Index • Participation Measure for Post-acute Care • Participation Objective, Participation Subjective • Participation Survey of Mobility Limited People • Physical Performance Battery for Patients with Cancer • Reintegration to Normal Living/Life Index • Six Minute Arm Test (6-MAT) • Short Performance Physical Battery • Timed 25 Foot Walk • Timed Up & Go (Cognitive and Manual) • Wolf Motor Function Scale

Appendix 2. Categories of Functional Mobility Testing and Respective Tests

Upper Extremity Functional Movement Tests	ADL Functional Tests Category (Physical and Self-report)	Walk Tests	Self-report Community Participation
<ul style="list-style-type: none"> • Action Research Arm Test • Activity Measure for Post-acute Care • Arm Motor Ability Test • Six Minute Arm Test (6-MAT) • Wolf Motor Function Scale 	<ul style="list-style-type: none"> • Assessment of Life Habits • Action Research Arm Test • Activity Measure for Post-acute Care • Arm Motor Ability Test • Canadian Occupational Performance Measure • Barthel Index • Functional Independence Measure/Functional Self-assessment 	<ul style="list-style-type: none"> • 2 Minute Walk Test • 6 Minute Walk Test • 12 Minute Walk Test • 10 Meter Walk Test • 5 Times Sit to Stand • Timed 25 Foot Walk • Timed Up & Go (Cognitive and Manual) • High-Level Mobility Assessment Tool (HiMAT) • Short Performance Physical Battery • Physical Performance Battery for Patients with Cancer 	<ul style="list-style-type: none"> • Impact on Participation and Autonomy Questionnaire (IPAQ) • Life Satisfaction Questionnaire (LSAT-9) • Functional Status Examination • Modified Rankin Scale • Participation Measure for Post-acute Care • Participation Objective • Participation Subjective (POPS) • Participation Survey of Mobility Limited People (PSM) • Reintegration to Normal Living/Life Index

Abbreviation: ADL, activities of daily living

REFERENCES

1. American Cancer Society . Cancer Facts and Figures 2015. 2015; <http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/>. Accessed July 14, 2015.
2. American Cancer Society. Breast Cancer Facts and Figures 2013-2014. 2013; <http://www.cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures>. Accessed July 14, 2015.
3. WHO | International Classification of Functioning, Disability and Health (ICF). 2015. <http://www.who.int/classifications/icf/en/>. Accessed July 14, 2015.
4. Levy E, Pfalzer L, Danoff J et al. Predictors of functional shoulder recovery at 1 and 12 months after breast cancer surgery. *Breast Cancer Res Treat.* 2012;134(1):315-324. doi: 10.1007/s10549-012-2061-1. Epub 2012 Apr 19.
5. Karki A, Simonen R, Malkia E, Selfe J. Impairments,

- activity limitations and participation restrictions 6 and 12 months after breast cancer operation. *J Rehabil Med*. 2005;37(3):180-188.
6. Levangie PK, Drouin J. Magnitude of late effects of breast cancer treatments on shoulder function: a systematic review. *Breast Cancer Res Treat*. 2009;116(1):1-15. doi: 10.1007/s10549-008-0246-4. Epub 2008 Nov 25.
 7. Hidding JT, Beurskens CH, Van Der Wees PJ, Van Laarhoven HW, Nijhuis-Van Der Sanden MW. Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review. *PLoS one*. 2014;9(5):e96748. doi: 10.1371/journal.pone.0096748. eCollection 2014.
 8. LeBlanc M, Stineman M, DeMichele A, Stricker C, Mao JJ. Validation of QuickDASH outcome measure in breast cancer survivors for upper extremity disability. *Arch Phys Med Rehabil*. 2014;95(3):493-498. doi: 10.1016/j.apmr.2013.09.016. Epub 2013 Oct 2.
 9. Ness KK, Wall MM, Oakes JM, Robison LL, Gurney JG. Physical performance limitations and participation restrictions among cancer survivors: a population-based study. *Ann Epidemiol*. 2006;16(3):197-205. Epub 2005 Aug 30.
 10. Sweeney C, Schmitz K, Lazovich D, Virnig B, Wallace R, Folsom A. Functional limitations in elderly female cancer survivors. *J Natl Cancer Inst*. 2006;98(8):521-529.
 11. Michael YL, Kawachi I, Berkman LF, Holmes MD, Colditz GA. The persistent impact of breast carcinoma on functional health status: prospective evidence from the Nurses' Health Study. *Cancer*. 2000;89(11):2176-2186.
 12. Campbell KL, Pusic AL, Zucker DS, et al. A prospective model of care for breast cancer rehabilitation: function. *Cancer*. 2012;118(8 Suppl):2300-2311. doi: 10.1002/cncr.27464.
 13. Harrington S, Michener LA, Kendig T, Miale S, George SZ. Patient-reported upper extremity outcome measures used in breast cancer survivors: a systematic review. *Arch Phys Med Rehabil*. 2014;95(1):153-162. doi: 10.1016/j.apmr.2013.07.022. Epub 2013 Aug 6.
 14. Schmitz KH, Speck RM, Rye SA, DiSipio T, Hayes SC. Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through Study. *Cancer*. 2012;118(8 Suppl):2217-2225. doi: 10.1002/cncr.27474.
 15. Hayes SC, Battistutta D, Parker AW, Hirst C, Newman B. Assessing task "burden" of daily activities requiring upper body function among women following breast cancer treatment. *Support Care Cancer*. 2005;13(4):255-265. Epub 2004 Nov 18.
 16. Harrington S, Padua D, Battaglini C, et al. Comparison of shoulder flexibility, strength, and function between breast cancer survivors and healthy participants. *J Cancer Surviv*. 2011;5(2):167-174. doi: 10.1007/s11764-010-0168-0. Epub 2011 Jan 12.
 17. Task Force on Standards for Measurement in Physical Therapy. Standards for tests and measurements in physical therapy practice. *Phys Ther*. 1991;71(8):589-622.
 18. Potter K, Fulk G, Salem Y, Sullivan J. Outcome measures in neurological physical therapy practice: part I. Making sound decisions. *J Neurol Phys Ther*. 2011;35(2):57-64. doi: 10.1097/NPT.0b013e318219a51a.
 19. Jette DU, Halbert J, Iverson C, Miceli E, Shah P. Use of standardized outcome measures in physical therapist practice: perceptions and applications. *Phys Ther*. 2009;89(2):125-135. doi: 10.2522/ptj.20080234. Epub 2008 Dec 12.
 20. Levangie P, Fisher, MI. Oncology Section Task Force on Breast Cancer Outcomes: an introduction to the EDGE task force and clinical measures of upper extremity function. *Rehabil Oncol*. 2013;31(1):6-10.
 21. Perdomo M, Sebeliski CA, Davies C. Oncology Section Task Force on Breast Cancer Outcomes: shoulder and glenohumeral outcome measures. *Rehabil Oncol*. 2013;31(1):19-26.
 22. Miale S, Harrington S, Kendig T. Oncology Section Task Force on Breast Cancer Outcomes: clinical measures of upper extremity function. *Rehabil Oncol*. 2013;31(1):27-34.
 23. Fisher MI, Levangie, P. Oncology Section Task Force on Breast Cancer Outcomes: scapular assessment. *Rehabil Oncol*. 2013;31(1):11-18.
 24. Fisher MI, Davies C, Beuthin C, Colon G, Zoll B, Pflazer L. Breast Cancer EDGE Task Force Outcomes-Clinical Measures of Strength and Muscular Endurance: a systematic review. *Rehabil Oncol*. 2014;32(4):6-15.
 25. Harrington S, Gilchrist L, Sander A. Breast Cancer EDGE Task Force Outcomes: clinical measures of pain. *Rehabil Oncol*. 2014;32(2):13-21.
 26. Price W, Doherty D, Adams A, Bohde E. Breast Cancer EDGE Task Force Outcomes: evidence-based cancer-related fatigue measurement tools. *Rehabil Oncol*. 2014;32(3):32-39.
 27. Huang M, Blackwood J, Croarkin E et al. Oncology Section Task Force on Breast Cancer Outcomes: clinical measures of balance – a systematic review. *Rehabil Oncol*. 2015;33(1):18-27.
 28. Harrington S, Miale S, Edbaugh D. Breast Cancer EDGE Task Force Outcomes: clinical measures of health related quality of life. *Rehabil Oncol*. 2015;33(1):5-17.
 29. Drouin J, Morris G. Breast cancer: systematic review of clinical measures of cardiorespiratory fitness tests. *Rehabil Oncol*. 2015; 33(2):24-36.
 30. Griffin J. *Client-Centered Exercise Prescription*. 3rd ed. Champaign, IL: Human Kinetics; 2015.
 31. Haley SM, Andres PL, Coster WJ, Kosinski M, Ni P, Jette AM. Short-form activity measure for post-acute care. *Arch Phys Med Rehabil*. 2004;85(4):649-660.
 32. Boston Rehabilitation Outcomes Center. Boston University Activity Measure for Post-Acute Care. <http://www.bu.edu/bostonroc/instruments/am-pac/>. Accessed July 14, 2015.
 33. Uniform Data System for Medical Rehabilitation. Functional Independence Measure. http://www.udsmr.org/WebModules/FIM/Fim_About.aspx. Accessed July 14, 2015.
 34. Coster WJ, Haley SM, Jette AM. Measuring patient-reported outcomes after discharge from inpatient rehabilitation settings. *J Rehabil Med*. 2006;38(4):237-242.

35. Cheville AL, Basford JR, Troxel AB, Kornblith AB. Performance of common clinician- and self-report measures in assessing the function of community-dwelling people with metastatic breast cancer. *Arch Phys Med Rehabil*. 2009;90(12):2116-2124. doi: 10.1016/j.apmr.2009.06.020.
36. Dodds TA, Martin DP, Stolov WC, Deyo RA. A validation of the functional independence measurement and its performance among rehabilitation inpatients. *Arch Phys Rehabil*. 1993;74(5):531-536.
37. Fougeyrollas P, Noreau L, Bergeron H, Cloutier R, Dion S, St-Michel G. Social consequences of long term impairments and disabilities: conceptual approach and assessment of handicap. *Int J Rehabil Res*. 1998;21(2):127-141.
38. Magasi S, Post M. A comparative review of contemporary participation measures' psychometric properties and content coverage. *Arch Phys Med Rehabil*. 2010;91(9 Suppl):S17-28. doi: 10.1016/j.apmr.2010.07.011.
39. ATS statement: guidelines for the six-minute walk test. *Am J Resp Crit Care Med*. 2002;166(1):111-117.
40. Schmidt K, Vogt L, Thiel C, Jager E, Banzer W. Validity of the six-minute walk test in cancer patients. *Int J Sports Med*. 2013;34(7):631-636. doi: 10.1055/s-0032-1323746. Epub 2013 Feb 26.
41. Scivoletto G, Tamburella F, Laurenza L, Foti C, Ditunno J, Molinari M. Validity and reliability of the 10-m walk test and the 6-min walk test in spinal cord injury patients. *Spinal Cord*. 2011;49(6):736-740. doi: 10.1038/sc.2010.180. Epub 2011 Jan 11.
42. Pollentier B, Irons S, Benedetto C, et al. Examination of the six minute walk test to determine functional capacity in people with chronic heart failure: a systematic review. *Cardiopulm Phys Ther J*. 2010;21(1):13-21.
43. Redelmeier D, Bayoumi A, Goldstein R, Guyatt G. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. *Am J Respir Crit Care Med*. 1997;155(4):1278-1282.
44. Ries JD, Echternach JL, Nof L, Gagnon Blodgett M. Test-retest reliability and minimal detectable change scores for the timed "up & go" test, the six-minute walk test, and gait speed in people with Alzheimer disease. *Phys Ther*. 2009;89(6):569-579. doi: 10.2522/ptj.20080258. Epub 2009 Apr 23.
45. Cheville A, Troxel A, Basford J, Kornblith A. Prevalence and treatment patterns of physical impairments in patients with metastatic breast cancer. *J Clin Oncol*. 2008;26(16):2621-2629.
46. Eyigor S, Karapolat H, Yesil H, Uslu R, Durmaz B. Effects of pilates exercises on functional capacity, flexibility, fatigue, depression and quality of life in female breast cancer patients: a randomized controlled study. *Eur J Phys Rehabil Med*. 2010;46(4):481-487.
47. Anderson RT, Kimmick GG, McCoy TP, et al. A randomized trial of exercise on well-being and function following breast cancer surgery: the RESTORE trial. *J Cancer Surviv*. 2012;6(2):172-181. doi: 10.1007/s11764-011-0208-4. Epub 2011 Dec 10.
48. Vincent F, Labourey JL, Leobon S, Antonini MT, Lavau-Denes S, Tubiana-Mathieu N. Effects of a home-based walking training program on cardiorespiratory fitness in breast cancer patients receiving adjuvant chemotherapy: a pilot study. *Eur J Phys Rehabil Med*. 2013;49(3):319-329. Epub 2013 Mar 13.
49. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc*. 1991;39(2):142-148.
50. Steffen T, Hacker T, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds. *Phys Ther*. 2002;82(2):128-137.
51. Onder G, Penninx B, Ferrucci L, Fried L, Guralnik J, Pahor M. Measures of physical performance and risk for progressive and catastrophic disability: results from the Women's Health and Aging Study. *J Gerontol A Biol Sci Med Sci*. 2005;60(1):74-79.
52. Nelson P, Hughes S, Virjee S, Beresford H, et al. Walking speed as a measure of disability. *Care Elderly*. 1991;3:125-126.
53. Wampler M, Topp K, Miaskowski C, Byl N, Rugo H, Hamel K. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. *Arch Phys Med Rehabil*. 2007;88(8):1002-1008.
54. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. *Chest*. 2001;119(1):256-270.
55. Bernstein M, Despars J, Singh N, Avalos K, Stansbury D, Light R. Reanalysis of the 12-minute walk in patients with chronic obstructive pulmonary disease. *Chest*. 1994;105(1):163-167.
56. Bohannon R. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. *Age Aging*. 1997;26(1):15-19.
57. Bohannon R, Fritz S, Lusardi M. Walking speed: the 6th vital sign. *J Geriatr Phys Ther*. 2009;32:2-5.
58. Guralnik J, Simonsick E, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol*. 1994;49(2):M85-94.
59. Guralnik J, Ferrucci L, Simonsick E, Salive M, Wallace R. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. *N Engl J Med*. 1995;332(9):556-561.
60. Curb J, Ceria-Ulep C, Rodriguez B, et al. Performance-based measures of physical function for high-function populations. *J Am Geriatr Soc*. 2006;54(5):737-742.
61. Simmonds M. Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery. *J Pain Symptom Manage*. 2002;24(4):404-414.
62. Bohannon R. Reference values for the five-repetition sit-to-stand test: a descriptive meta-analysis of data from elders. *Percept Mot Skills*. 2006;103(1):215-222.

63. Andres P, Haley S, Ni P. Is patient-reported function reliable for monitoring postacute outcomes? *Am J Phys Med Rehabil.* 2003;82(8):614-621.
64. Jette A, Haley S, Tao W, et al. Prospective evaluation of the AM-PAC-CAT in outpatient rehabilitation settings. *Phys Ther.* 2007;87(4):385-398.
65. Cheville A, Yost K, Larson D, et al. Performance of an item response theory-based computer adaptive test in identifying functional decline. *Arch Phys Med Rehabil.* 2012;93(7):1153-1160.
66. Latham N, Mehta V, Nguyen A, et al. Performance-based or self-report measures of physical function: which should be used in clinical trials of hip fracture patients? *Arch Phys Med Rehabil.* 2008;89(11):2146-2155.
67. Haley S, Coster W, Andres L, et al. Activity outcome measurement for postacute care. *Med Care.* 2004;42(1):I49-I61.
68. Ottenbacher K, Hsu Y, Granger C, Fiedler R. The reliability of the functional independence measure: a quantitative review. *Arch Phys Med Rehabil.* 1996;77(12):1226-1232.
69. Pollak N, Rheault W, Stoecker J. Reliability and validity of the FIM for persons aged 80 years and above from a multi-level continuing care retirement community. *Arch Phys Med Rehabil.* 1996;77(10):1056-1061.
70. Hobart J, Lamping D, Freeman J, et al. Evidence-based measurement: which disability scale for neurologic rehabilitation? *Neurology.* 2001;57(4):639-644.
71. Hsueh I, Lin J, Jeng J, Hsieh C. Comparison of the psychometric characteristics of the functional independence measure, 5 item Barthel index, and 10 item Barthel index in patients with stroke. *J Neurol Neurosurg Psychiatr.* 2002;73(2):188-190.
72. Desrosiers J, Rochette A, Noreau L, Bourbonnais D, Bravo G, Bourget A. Long-term changes in participation after stroke. *Top Stroke Rehabil.* 2006;13(4):86-96.
73. Noreau L, Desrosiers J, Robichaud L, Fougereyrollas P, Rochette A, Viscogliosi C. Measuring social participation: reliability of the LIFE-H in older adults with disabilities. *Disabil Rehabil.* 2004;26(6):346-352.
74. Poulin V, Desrosiers J. Reliability of the LIFE-H satisfaction scale and relationship between participation and satisfaction of older adults with disabilities. *Disabil Rehabil.* 2009;31(16):1311-1317.
75. Noreau L, Fougereyrollas P, Vincent C. The LIFE-H: Assessment of the quality of social participation. *Technol Disabil.* 2002;14(3):113-118.
76. Resnik L, Borgia M. Reliability of outcome measures for people with lower-limb amputations: distinguishing true change from statistical error. *Phys Ther.* 2011;91(4):555-565.
77. Brooks D, Hunter J, Parsons J, Livsey E, Quirt J, Devlin M. Reliability of the two-minute walk test in individuals with transtibial amputation. *Arch Phys Med Rehabil.* 2002;83(11):1562-1565.
78. Rossier P, Wade D. Validity and reliability comparison of 4 mobility measures in patients presenting with neurologic impairment. *Arch Phys Med Rehabil.* 2001;82(1):9-13.
79. Hiengkaew V, Jitree K, Chaipayat P. Minimal detectable changes of the Berg Balance Scale, Fugl-Meyer Assessment Scale, Timed "Up & Go" Test, gait speeds, and 2-minute walk test in individuals with chronic stroke with different degrees of ankle plantarflexor tone. *Arch Phys Med Rehabil.* 2012;93(7):1201-1208.
80. Miller P, Moreland J, Stevenson T. Measurement properties of a standardized version of the two-minute walk test for individuals with neurological dysfunction. *Physiother Can.* 2002;54(4):241-248.
81. Guyatt G, Pugsley S, Sullivan M, et al. Effect of encouragement on walking test performance. *Thorax.* 1984;39(11):818-822.
82. Connelly D, Thomas B, Cliffe S, Perry W, Smith R. Clinical utility of the 2-minute walk test for older adults living in long-term care. *Physiother Can.* 2009;61(2):78-87.
83. Brooks D, Davis A, Naglie G. The feasibility of six-minute and two-minute walk tests in in-patient geriatric rehabilitation. *Can J Aging.* 2007;26(02):159-162.
84. Gijbels D, Eijnde B, Feys P. Comparison of the 2- and 6-minute walk test in multiple sclerosis. *Mult Scler.* 2011;17(10):1269-1272. doi: 10.1177/1352458511408475. Epub 2011 Jun 3.
85. Kosak M, Smith T. Comparison of the 2-, 6-, and 12-minute walk tests in patients with stroke. *J Rehabil Res Dev.* 2005;42:103-107.
86. Harada N, Chiu V, Stewart A. Mobility-related function in older adults: assessment with a 6-minute walk test. *Arch Phys Med Rehabil.* 1999;80(7):837-841.
87. Kennedy DM, Stratford PW, Wessel J, Gollish JD, Penney D. Assessing stability and change of four performance measures: a longitudinal study evaluating outcome following total hip and knee arthroplasty. *BMC Musculoskelet Disord.* 2005;6:3.
88. Steffen T, Seney M. Test-retest reliability and minimal detectable change on balance and ambulation tests, the 36-item short-form health survey, and the unified Parkinson disease rating scale in people with parkinsonism. *Phys Ther.* 2008;88(6):733-746.
89. Eng J, Dawson A, Chu K. Submaximal exercise in persons with stroke: test-retest reliability and concurrent validity with maximal oxygen consumption. *Arch Phys Med Rehabil.* 2004;85(1):113-118.
90. Flansbjerg U, Holmback A, Downham D, Patten C, Lexell J. Reliability of gait performance tests and women with hemiparesis after stroke. *J Rehabil Med.* 2005;37(2):75-82.
91. Mossberg K. Reliability of a timed walk test in persons with acquired brain injury. *American J Phys Med Rehabil.* 2003;82(5):385-390.
92. Steffen T, Hacker T, Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and gait speeds. *Phys Ther.* 2002;82(2):128-137.
93. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc.* 2006;54:743-749.

94. Lam T, Noonan V, Eng J. A systematic review of functional ambulation outcome measures in spinal cord injury. *Spinal Cord*. 2008;46(4):246-254.
95. Van Hedel H, Wirz M, Dietz V. Assessing walking ability in subjects with spinal cord injury: validity and reliability of 3 walking tests. *Arch Phys Med Rehabil*. 2005;86(2):190-196.
96. Wolf S, Catlin P, Gage K, Gurucharri K, Robertson R, Stephen K. Establishing the reliability and validity of measurements of walking time using the Emory Functional Ambulation Profile. *Phys Ther*. 1999;79(12):1122-1133.
97. Watson M. Refining the ten-metre walking test for use with neurologically impaired people. *Physiotherapy*. 2002;88(7):386-397.
98. Hollman J, Beckman B, Brandt R, Merriwether E, Williams R, Nordrum J. Minimum detectable change in gait velocity during acute rehabilitation following hip fracture. *J Geriatr Phys Ther*. 2008;31(2):53-56.
99. Bowden M, Balasubramanian C, Behrman A, Kautz S. Validation of a speed-based classification system using quantitative measures of walking performance poststroke. *Neurorehabil Neural Repair*. 2008;22(6):672-675.
100. Van Loo M, Moseley A, Bosman J, De Bie R, Hassett L. Test-re-test reliability of walking speed, step length and step width measurement after traumatic brain injury: a pilot study. *Brain Inj*. 2004;18(10):1041-1048.
101. Burns AS, Delparte JJ, Patrick M, Marino RJ, Ditunno JF. The reproducibility and convergent validity of the walking index for spinal cord injury (WISCI) in chronic spinal cord injury. *Neurorehabil Neural Repair*. 2011;25(2):149-157. doi: 10.1177/1545968310376756.
102. Paltamaa J, Sarasoja T, Leskinen E, Wikström J, Mälkiä E. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. *Arch Phys Med Rehabil*. 2007;88(12):1649-1657.
103. Tyson S, Connell L. The psychometric properties and clinical utility of measures of walking and mobility in neurological conditions: a systematic review. *Clin Rehabil*. 2009;23(11):1018-1033.
104. De Buyser S, Petrovic M, Taes Y, Toye K, Kaufman J-M, Goemaere S. Physical function measurements predict mortality in ambulatory older men. *Eur J Clin Invest*. 2013;43(4):379-386. doi: 10.1111/eci.12056. Epub 2013 Feb 10.
105. Alibhai S, Breunis H, Timilshina N, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. *J Clin Oncol*. 2010;28(34):5038-5045.
106. Overcash J, Rivera H. Physical performance evaluation of older cancer patients: a preliminary study. *Crit Rev Oncol Hematol*. 2008;68(3):233-241.
107. Brooks D, Davis AM, Naglie G. Validity of 3 physical performance measures in inpatient geriatric rehabilitation. *Arch Phys Med Rehabil*. 2006;87(1):105-110.
108. Duncan R, Leddy A, Earhart G. Five times sit-to-stand test performance in Parkinson's disease. *Arch Phys Med Rehabil*. 2011;92(9):1431-1436. doi: 10.1016/j.apmr.2011.04.008.
109. Simmonds M, Olson S, Jones S, et al. Psychometric characteristics and clinical usefulness of physical performance tests in patients with low back pain. *Spine*. 1998;23(22):2412-2421.
110. Mong Y, Teo TW, Ng SS. 5-repetition sit-to-stand test in subjects with chronic stroke: reliability and validity. *Arch Phys Med Rehabil*. 2010;91(3):407-413. doi: 10.1016/j.apmr.2009.10.030.
111. Schaubert K, Bohannon R. Reliability and validity of three strength measures obtained from community-dwelling elderly persons. *J Strength Cond Res*. 2005;19(3):717-720.
112. Tiedemann A, Shimada H, Sherrington C, Murray S, Lord S. The comparative ability of eight functional mobility tests for predicting falls in community-dwelling older people. *Age Aging*. 2008;37(4):430-435.
113. Bohannon R, Shove M, Barreca S, Masters L, Sigouin C. Five-repetition sit-to-stand test performance by community-dwelling adults: A preliminary investigation of times, determinants, and relationship with self-reported physical performance. *Isokinet Exerc Sci*. 2007;15(2):77-81.
114. Lin Y, Davey R, Cochrane T. Tests for physical function of the elderly with knee and hip osteoarthritis. *Scand J Med Sci Sports*. 2001;11(5):280-286.
115. Goldberg A, Chavis M, Watkins J, Wilson T. The five-times-sit-to-stand test: validity, reliability and detectable change in older females. *Aging Clin Exp Res*. 2012;24(4):339-344.
116. Meretta BM, Whitney SL, Marchetti GF, Sparto PJ, Muirhead RJ. The five times sit to stand test: responsiveness to change and concurrent validity in adults undergoing vestibular rehabilitation. *J Vestib Res*. 2006;16(4-5):233-243.
117. Ozalevli S, Ozden A, Itil O, Akkoçlu A. Comparison of the sit-to-stand test with 6min walk test in patients with chronic obstructive pulmonary disease. *Resp Med*. 2007;101(2):286-293.
118. Studenski S, Perera S, Wallace D, et al. Physical performance measures in the clinical setting. *J Am Geriatr Soc*. 2003;51(3):314-322.
119. Ostir G, Volpato S, Fried L, Chaves P, Guralnik J. Reliability and sensitivity to change assessed for a summary measure of lower body function: results from the Women's Health and Aging Study. *J Clin Epidemiol*. 2002;55(9):916-921.
120. Gómez JF, Curcio CL, Alvarado B, Zunzunegui MV, Guralnik J. Validity and reliability of the Short Physical Performance Battery (SPPB): a pilot study on mobility in the Colombian Andes. *Colomb Med (Cali)*. 2013;44(3):165-171.
121. Freire A, Guerra R, Alvarado B, Guralnik J, Zunzunegui M. Validity and reliability of the short physical performance battery in two diverse older adult populations in Quebec and Brazil. *J Aging Health*. 2012;24(5):863-878. doi: 10.1177/0898264312438551. Epub 2012 Mar 15.
122. Mangione KK, Craik RL, McCormick AA, et al. Detectable changes in physical performance measures in elderly African Americans. *Phys Ther*. 2010;90(6):921-927. doi: 10.2522/ptj.20090363. Epub 2010 Apr 15.